Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center

Bone Marrow Transplantation volume 25, pages 35–40 (2000)Cite this article

Abstract

It is now established that a subgroup of non-Hodgkin's lymphoma (NHL) patients probably benefit from high-dose therapy (HDT). We therefore retrospectively analyzed survival of 126 consecutive patients with large cell lymphoma (LCL) and high–intermediate (HI) or high-risk (H) age-adjusted international prognostic index (Aa-IPI). They received either standard chemotherapy (CT) (66 patients), or HDT (60 patients). Distribution of the Aa-IPI scores showed no statistical significant difference between the two treatment groups. Complete response (CR) rate was 51% for the whole series, with 41% and 62% for the standard CT group and HDT group, respectively. With a median follow-up of 63 months (range, 16 to 159), the 5-year overall survival (OS) and event-free survival (EFS) for all patients was 52% and 43%, respectively. There was a statistical significant difference in terms of survival towards the HDT group: OS at 76% vs 31%, EFS at 64% vs 24%. Patients who achieved CR with front-line therapy had a 5-year OS at 70%, while it was 34% for patients who were not in CR. These results are comparable to those reported in the literature, and strongly suggest that both initial CR achievement and HDT as front-line treatment are predictive factors for prolonged survival of patients with poor-risk LCL. Bone Marrow Transplantation (2000) 25, 35–40.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Harris NL, Jaffe ES, Stein H et al. A revised European American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  PubMed  Google Scholar 

  2. Fisher RI, De Vita VT Jr, Johnson BL et al. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy Am J Med 1977 63: 177–182

    Article  CAS  Google Scholar 

  3. Laurence J, Coleman M, Allen SL et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen Ann Intern Med 1982 97: 190–195

    Article  CAS  Google Scholar 

  4. Klimo P, Connors JM . MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma Ann Intern Med 1985 102: 596–602

    Article  CAS  Google Scholar 

  5. Shipp MA, Harrington DP, Klatt MM et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD Ann Intern Med 1986 104: 757–765

    Article  CAS  Google Scholar 

  6. Fisher RI, Gaynor ER, Dahlberg S et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma New Engl J Med 1993 328: 1002–1006

    Article  CAS  Google Scholar 

  7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987–994

    Article  Google Scholar 

  8. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma. Updated results of the prospective study LNH 87–2 J Clin Oncol 1997 15: 1131–1137

    Article  CAS  Google Scholar 

  9. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma New Engl J Med 1997 336: 1290–1297

    Article  CAS  Google Scholar 

  10. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group J Clin Oncol 1998 16: 2796–2802

    Article  CAS  Google Scholar 

  11. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 regimen. A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma J Clin Oncol 1989 7: 1018–1026

    Article  CAS  Google Scholar 

  12. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1997 15: 1722–1729

    Article  CAS  Google Scholar 

  13. Armitage JO, Cheson BD . Interpretation of clinical trials in diffuse large-cell lymphoma J Clin Oncol 1988 6: 1335–1347

    Article  CAS  Google Scholar 

  14. Shipp MA, Abeloff MD, Antman KH et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury J Clin Oncol 1999 17: 423–429

    Article  CAS  Google Scholar 

  15. Reyes F, Lepage E, Morel P et al. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (pts) with aggressive lymphoma: updated results of the randomized LNH93–3 study Blood 1998 90: (Suppl. 1) 594a

    Google Scholar 

  16. Kaiser U, Uebelacker I, Havemann K . on behalf of the German High Grade Lymphoma Study Group, Marburg, Germany High-dose chemotherapy with autologous stem cell transplantation in high grade NHL: first analysis of a randomized multicenter study Bone Marrow Transplant 1998 21: (Suppl. 1) S177

    Google Scholar 

  17. Haq R, Sawka CA, Franssen E, Berinstein NL . Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review J Clin Oncol 1994 12: 1074–1084

    Article  Google Scholar 

  18. Verdonck LF, van Putten WL, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma New Engl J Med 1995 332: 1045–1051

    Article  CAS  Google Scholar 

  19. Martelli M, Vignetti M, Zinzani P et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatine, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study J Clin Oncol 1996 14: 534–542

    Article  CAS  Google Scholar 

  20. Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma J Clin Oncol 1997 15: 491–498

    Article  CAS  Google Scholar 

  21. Nademanee A, Molina A, O'Donnell MR et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma. International index high and high–intermediate risk group Blood 1997 90: 3844–3852

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Institut Paoli-Calmettes, Regional Cancer Center-Université de la Méditerranée, Marseille, France

    R Bouabdallah, D Coso, R Costello, D Blaise, D Maraninchi & JA Gastaut

  2. Department of Biology, Institut Paoli-Calmettes, Regional Cancer Center-Université de la Méditerranée, Marseille, France

    L Xerri & D Sainty

  3. Department of Biostatistics and Medical Information, Institut Paoli-Calmettes, Regional Cancer Center-Université de la Méditerranée, Marseille, France

    VJ Bardou

Authors
  1. R Bouabdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Coso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. VJ Bardou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Xerri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Sainty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Maraninchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. JA Gastaut
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bouabdallah, R., Coso, D., Costello, R. et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. Bone Marrow Transplant 25, 35–40 (2000). https://doi.org/10.1038/sj.bmt.1702080

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702080

Keywords

This article is cited by

Search

Advanced search

Quick links